Cite
Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis. 2021;doi: 10.1093/ecco-jcc/jjab153.
Chanchlani, N., Lin, S., Chee, D., Hamilton, B., Nice, R., Zehra, A., Bewshea, C., Cipriano, B., Derikx, L. A. A. P., Dunlop, A., Greathead, L., Griffiths, R. L., Ibraheim, H., Kelleher, P., Kok, K. B., Lees, C. W., MacDonald, J., Sebastian, S., Smith, P. J., McDonald, T. J., Irving, P. M., Powell, N., Kennedy, N. A., Goodhand, J. R., & Ahmad, T. (2021). Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjab153
Chanchlani, Neil, et al. "Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients." Journal of Crohn's & colitis vol. (2021). doi: https://doi.org/10.1093/ecco-jcc/jjab153
Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Zehra A, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, Greathead L, Griffiths RL, Ibraheim H, Kelleher P, Kok KB, Lees CW, MacDonald J, Sebastian S, Smith PJ, McDonald TJ, Irving PM, Powell N, Kennedy NA, Goodhand JR, Ahmad T. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis. 2021 Sep 02; doi: 10.1093/ecco-jcc/jjab153. Epub 2021 Sep 02. PMID: 34473254; PMCID: PMC8499950.
Copy
Download .nbib